drugset
drugset / Trial / NCT00625872

Neuromuscular Changes In Small For Gestational Age Children During Somatropin Therapy

NCT00625872 ↗

Phase 3 Terminated 23 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The planned study focuses on the effect of a one year Somatropin treatment (0.035 mg/kg/d or 0.067 mg/kg/d) in short children born SGA on neuromuscular function and cognitive performance.

Timeline

Start
2008-07
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 0.035 mg/kg —
Subject Somatropin Protein / enzyme biologic 0.067 mg/kg —

Indications

fetal growth restriction